Agendia, Inc., Knoxville Comprehensive Breast Center, PLLC, And Knoxville Dermatopathology Laboratory, LLC Agree To Settle False Claims Act Allegations For More Than $3,750,000
KNOXVILLE, Tenn. – Agendia, Inc., a global molecular diagnostics company that offers genomic testing designed to profile certain types of breast cancer, including a lab test called MammaPrint, agreed to settle allegations under the False Claims Act (FCA) that the company submitted deceptive claims for reimbursement for MammaPrint genomic tests to government health care benefit programs. Under the terms of the settlement, Agendia will pay at least $3,250,000 and potentially additional sums if the privately held Company is sold. In separate settlements, Knoxville Comprehensive Breast Center (KCBC) and Knoxville Dermatopathology Laboratory (KDL) agreed to resolve related FCA allegations for $322,500 and $207,500, respectively.
Action Details
- Date:May 21, 2025
- Agency:U.S. Attorney's Office, Eastern District of Tennessee
-
Enforcement Types:
- Criminal and Civil Actions